Oncolytics Biotech to Initiate Phase II Cancer Combination Therapy Trial
Posted on: Friday, 20 June 2008, 09:00 CDT
Oncolytics Biotech has announced that following FDA review, the company is initiating a US Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
This trial is a 14-patient, single-arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin.
Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.
The primary objective of the Phase II trial is to measure tumor responses and duration of response, and to describe any evidence of antitumor activity. The secondary objective is to determine the safety and tolerability of Reolysin when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.
Source: Datamonitor
Related Articles
- Advances in lung cancer research announced
- BioAlliance Pharma Suspends the Phase II/III Trial of Doxorubicin Transdrug(R) in Primary Liver Cancer
- Nuvera Biosciences Presents Advances in Breast Cancer Genomic Assays at ASCO Annual Meeting
- Rosetta Genomics Signs Research Agreement With Columbia University Medical Center to Advance Its Lead Cancer Diagnostics Program
- Exelixis Initiates Phase II Trial of XL880 in Patients With Gastric Cancer
- IOERT Shown to Be Highly Effective in Treating Locally Advanced Head and Neck Cancer
- Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients With Hormone Dependent Prostate Cancer
- New Advances in Breast Cancer Treatment Fueled By BCRF Support
- A Phase I Trial Combining High-Dose ^Sup 90^Y-Labeled Humanized Anti- CEA Monoclonal Antibody With Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
- Advancing the Standards of Endocrine Care: AACE Scientific Conference Highlights Putting Science into Practice
 |
 |
User Comments (0)
RSS Feeds